BOEHRINGER INGELHEIM ANIMAL HEALTH and ALGENEX S.L. are proud to announce the closing of a worldwide license agreement, allowing BOEHRINGER INGELHEIM to use the ALGENEX Top-Bac® technology.
Top-Bac®, is a proprietary technology, that significantly improves the productionyield and also the quality of proteins by using these improved baculovirus-based vector system applications in insect cells. Top-Bac® allows better utilization of resources since modern bioreactor technology can be applied without the need of components from animal origin. This follows an international trend in the vaccine development business.
“Partnering has been a central part of our company’s strategy for many years. We are excited about this opportunity, which complements our portfolio of core technologies. We are optimistic that TopBac® will help us to bring more innovative vaccines for animals to farmers and veterinarians,” says Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim.
“It goes without saying that a global license to a partner like BOEHRINGER INGELHEIM ANIMAL HEALTH is for ALGENEX a major recognition of its patented technologies related to baculovirus vectors. For a decade, we have noticed an increased demand from the diagnostics, human, and animal health market for better production platforms based on insect cells. With this additional deal with BOEHRINGER INGELHEIM ANIMAL HEALTH, we are happy to contribute significantly to this market development. We strongly believe that our technical and scientific developments should be as close as possible to the end user, allowing ALGENEX to improve and adapt constantly its innovative technologies, IBES®, CrisBio and Top- Bac®, to meet new customers’ needs.” says Dr. Jose Escribano, founder and scientific advisor for ALGENEX.
and powerful, to produce high added value molecules to both human and animal health in a cost-effective manner. In addition to the Top-Bac® technology, Algenex has also developed the IBES® and CrisBio technologies, which are based on the use of insects as disposable, living bioreactors. The combination of the three technologies leads to unprecedented production yields.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
For more information please visit http://www.boehringer-ingelheim.com